Five-day therapy with cephradine capsules, 500 mg BID, for the treatment of acute, uncomplicated urinary tract infections.
This double-blind, randomized multi-center study compared the efficacy and safety of a five-day treatment regimen with that of a ten-day treatment regimen for acute, uncomplicated urinary tract infections. All patients received cephradine capsules, 500 mg BID. Efficacy was evaluated in 71 patients (38 with five days of treatment; 33 with ten days of treatment). All but one patient in each group had a rapid resolution of symptoms. At the completion of treatment, cephradine eradicated the causative pathogen in 97.4% and 96.9% of patients in the two groups, respectively. One week after therapy, 86.8% of patients in the five-day treatment group and 84.8% of those in the ten-day treatment group maintained both complete resolution of symptoms and bacterial eradication. The incidence of side effects was equally low in the two groups. Thus a five-day regimen of cephradine, 500 mg BID, offers the potential advantages of cost-efficiency and improved patient compliance, while maintaining clinical efficacy in treating acute, uncomplicated urinary tract infections.